Gerhard Schaenzle

USPTO Granted Patents = 37 (Patent Applications = 5)

CIPO Patents = 5

EPO Patents = 18 (Patent Applications = 20)

Average Co-Inventor Count = 8.4

ph-index = 6

Forward Citations = 198(Granted Patents)

Location History:

Biberach-Mettenberg, DE (2007 - 2010)
Warthausen, DE (2012 - 2014)
Biberach, DE (2008 - 2015)
Biberach an der Riss, DE (2014 - 2016)

Company Filing History:

36 out of 1,536

Boehringer Ingelheim International Gmbh

patents

1 out of 194

Boehringer Ingelheim Pharma Gmbh & Co Kg

patents

Years Active: 2007-2016

Loading Chart...

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9328120 - 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders (2016-05-03),

2. 9199937 - Substituted quinolines and their use as medicaments (2015-12-01),

3. 9187478 - Substituted naphthyridines and their use as medicaments (2015-11-17),

4. 9102679 - Compounds for the treatment of CNS disorders (2015-08-11),

5. 9096603 - 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators (2015-08-04),

6. 9079905 - Compounds for the treatment of CNS disorders (2015-07-14),

7. 8969568 - Substituted naphthyridines and their use as medicaments (2015-03-03),

8. 8952014 - Pyrimidine derivatives which are CGRP—antagonists (2015-02-10),

9. 8912201 - 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders (2014-12-16),

10. 8912173 - Substituted quinolines and their use as medicaments (2014-12-16),

11. 8829006 - Compounds (2014-09-09),

12. 8765763 - Substituted piperazines as CGRP antagonists (2014-07-01),

13. 8648085 - 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders (2014-02-11),

14. 8629137 - CGRP antagonists (2014-01-14),

15. 8623901 - Compounds for the treatment of CNS disorders (2014-01-07),

Hello! I'm glad you're interested in learning about inventor Gerhard Schaenzle from Biberach, DE, who holds an impressive 37 patents. Let's dive into his innovative work and contributions to the field of CNS disorder treatments.

Title: Exploring the Innovations of Gerhard Schaenzle in CNS Disorders Treatment

Introduction: Gerhard Schaenzle is a prolific inventor based in Biberach, DE, known for his groundbreaking work in developing novel compounds for the treatment of conditions related to deficits in perception, concentration, learning, and memory.

Latest Patents: Two of his latest patents are centered around 6-cycloalkyl-pyrazolopyrimidinones and substituted quinolines. The former targets CNS disorders like Alzheimer's disease and schizophrenia by offering PDE9 inhibiting properties. The latter focuses on the development of medicaments using substituted quinolines, showcasing his diverse expertise in pharmaceutical innovation.

Career Highlights: Schaenzle has brought his visionary ideas to life working at renowned companies like Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharma GmbH & Co. KG, where he has undoubtedly made significant contributions to the advancement of pharmacological treatments.

Collaborations: Throughout his career, Schaenzle has collaborated closely with esteemed professionals in the field, including Stephan Georg Mueller and Klaus Rudolf. These collaborations have played a vital role in bringing his inventions to fruition and shaping the future of CNS disorder therapeutics.

Conclusion: Gerhard Schaenzle's relentless pursuit of innovation in the pharmaceutical industry has led to the development of cutting-edge compounds for treating CNS disorders. His remarkable patents and collaborations underscore his dedication to making a meaningful impact on healthcare.

This text is generated by artificial intelligence and may not be accurate.